Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 451902
Howard Hughes  |  by www.tradingmarkets.com. All rights reserved. 6.11 | 20:41

Receive Dave's best setups each evening from his favorite trading patterns.

Let Gary Kaltbaum send you timely emails to alrt when breakouts occure.
Every day receive the best plan of attack for the next day's trading directly from professional trader Kevin Haggerty.

(RTTNews) - Palo Alto-based Biopharmaceutical company CV Therapeutics, Inc. ( | | | ) on Wednesday said that it sent a termination notice to Solvay Pharmaceuticals, Inc. under the companies' co-promotion agreement for ACEON or perindopril erbumine Tablets.

CV Therapeutics stated that within the next several weeks it would conclude its promotion of ACEON. CV Therapeutics noted that there are no financial commitments for either company in connection with the co-promotion agreement termination. Further, it is not expecting any revenues from ACEON, CV Therapeutics added.

"We are excited to focus our promotional efforts on Ranexa, as we continue to see growing interest in the cardiology community," said CV Therapeutics, chairman and chief executive officer Louis Lange in a statement. CVTX closed Tuesday's regular trading session at $11.91, down $0.

02, on a volume of 763K shares.

Read more on by www.tradingmarkets.com. All rights reserved.
Keywords: Cv Therapeutics
Related news
Post comments
Name
Place
1 + 2 =
Comments